ADMA
ADMA BIOLOGICS, INC.
Biological Products, (No Diagnostic Substances)- 売上
- $510m
- 時価総額
- $2.1bn
株価 $8.79 · 100株 879円
免疫不全患者や感染症リスクのある患者向けに特殊生物製剤を製造販売し血漿由来治療薬を開発する
| 期 | 23/12 | 24/12 | 25/12 |
|---|---|---|---|
| 売上 | $258m | $426m | $510m |
| 成長率 | — | 65.2% | 19.6% |
| 総利益 | $89m | $220m | $293m |
| 総利益率 | 34.4% | 51.5% | 57.4% |
| 販管費 | $59m | $74m | $92m |
| 販管費率 | 22.9% | 17.4% | 18.0% |
| 営利 | $22m | $139m | $191m |
| 営利率 | 8.4% | 32.6% | 37.5% |
| 純利益 | ▲$28m | $198m | $147m |
| PBR | 15.5 | 6.0 | 4.4 |
| PSR | 8.1 | 4.9 | 4.1 |
| PGPR | 23.5 | 9.5 | 7.1 |
| PER | — | 11 | 14 |
| ﾈｯﾄｷｬｯｼｭ | $51m | $31m | $15m |
| EV/EBITDA | 69.8 | 14.0 | 10.4 |
| Rule of 40 | — | 98% | 57% |
| セールス効率 | — | 865% | 419% |
※Rule of 40は売上成長率＋営業利益率、セールス効率は売上総利益増加÷販管費増加（販管費増のときのみ）